ZELTIQ Aesthetics (ZLTQ) Shares are Up 7.84%

ZELTIQ Aesthetics (ZLTQ) : Traders are bullish on ZELTIQ Aesthetics (ZLTQ) as it has outperformed the S&P 500 by a wide margin of 20.08% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 7.78%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 7.84% in the last 1 week, and is up 21.32% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 11.77% and the 50-Day Moving Average is 23.85%. ZELTIQ Aesthetics (NASDAQ:ZLTQ): stock turned positive on Friday. Though the stock opened at $36.63, the bulls momentum made the stock top out at $38.57 level for the day. The stock recorded a low of $36.4 and closed the trading day at $37.84, in the green by 2.30%. The total traded volume for the day was 1,236,173. The stock had closed at $36.99 in the previous days trading.


The company Insiders own 21.7% of ZELTIQ Aesthetics shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -3.04% . During last six month period, the net percent change held by insiders has seen a change of -13.67%. Also, JP Morgan maintains its rating on ZELTIQ Aesthetics (NASDAQ:ZLTQ). The global brokerage major raises the current price target from $27 per share to $35 per share. Analysts at the JP Morgan have a current rating of Neutral on the shares. The rating by the firm was issued on August 9, 2016.

ZELTIQ Aesthetics, Inc. is a medical technology company. The Company is focused on developing and commercializing products utilizing its controlled-cooling technology platform. Its commercial product, the CoolSculpting System, is designed to reduce stubborn fat bulges. The Company sells its CoolSculpting system to dermatologists, plastic surgeons and aesthetic specialists and generates revenue from sales of its CoolSculpting system and from sales of consumables to its customers. Consumables are the CoolSculpting procedure packs that it sells, which are needed to perform procedures using its CoolSculpting system. As of December 31, 2014, it had an installed base of 3,176 CoolSculpting systems installed across approximately 2,688 practices across the world. As of December 31, 2014, 1.5 million CoolSculpting cycles had been shipped to its customers and distributors.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.